Vincristine

證據等級: L5

預測適應症: 3 個

Vincristine: From Hematologic and Pediatric Solid Tumor Chemotherapy to Ganglioneuroblastoma

One-Sentence Summary

Vincristine is a vinca alkaloid chemotherapy agent widely used as a component of combination regimens for leukemia, lymphoma, and pediatric solid tumors. The TxGNN model predicts it may be effective for Ganglioneuroblastoma, with 4 clinical trials and 6 publications currently supporting this direction — several of which already show vincristine being used clinically in this exact disease.

Quick Overview

Item	Content
Original Indication	Not specified in the evidence pack; vincristine is a well-established component of combination chemotherapy for hematologic malignancies (leukemia, lymphoma) and pediatric solid tumors
Predicted New Indication	Ganglioneuroblastoma
TxGNN Prediction Score	99.31%
Evidence Level	L3
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack. Based on general pharmacological knowledge, vincristine is a vinca alkaloid that binds tubulin and inhibits microtubule assembly, arresting tumor cells in the M phase of mitosis. This mitotic-inhibition mechanism underlies its broad activity across rapidly dividing malignant cells and is why it forms the backbone (“V” in VAC, OPEC, and similar regimens) of many pediatric oncology protocols.

Ganglioneuroblastoma is a tumor of the sympathetic nervous system within the neuroblastic tumor family (spanning neuroblastoma to ganglioneuroma), and it is treated with the same combination chemotherapy backbones used for neuroblastoma. Notably, the literature evidence retrieved for this candidate already documents vincristine being used clinically to treat ganglioneuroblastoma (e.g., in combination with cisplatin, doxorubicin, and cyclophosphamide), and the associated Phase 2/3 trials target the broader “high-risk neuroblastoma/ganglioneuroblastoma” disease category. This suggests the TxGNN prediction is recovering an already-established clinical practice pattern rather than proposing a novel mechanistic hypothesis — which strengthens biological plausibility, though it also means the “new indication” framing should be interpreted as formalizing existing off-label/protocol use rather than a genuinely novel therapeutic direction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03786783	Phase 2	Active, not recruiting	42	Pilot induction regimen adding dinutuximab and sargramostim to chemotherapy for newly diagnosed high-risk neuroblastoma
NCT03126916	Phase 3	Recruiting	750	131I-MIBG or ALK inhibitor (lorlatinib) added to intensive standard therapy for newly diagnosed high-risk neuroblastoma/ganglioneuroblastoma
NCT06172296	Phase 3	Recruiting	478	Dinutuximab added to intensive multimodal therapy (induction chemo, surgery, transplant, immunotherapy) for newly diagnosed high-risk neuroblastoma
NCT01798004	Phase 1	Completed	150	Myeloablative busulfan/melphalan consolidation following induction chemotherapy for newly diagnosed high-risk neuroblastoma

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8255850	1993	Case report	Postgraduate Medical Journal	Spinal ganglioneuroblastoma achieved complete response with chemotherapy (including vincristine) alone, without surgery or radiotherapy
15701990	2005	Case report	Journal of Pediatric Hematology/Oncology	Ganglioneuroblastoma presenting with obstructive jaundice, treated with cisplatin/doxorubicin/cyclophosphamide/vincristine regimen
31342649	2019	Prospective clinical trial	Pediatric Blood & Cancer	Image-defined risk factors used to guide surgical timing in low-risk neuroblastoma disease (Japan Children’s Cancer Group)
3071124	1988	Case report	Hinyokika Kiyo	Multimodality treatment of adult adrenal ganglioneuroblastoma with regional lymph node metastasis
8888754	1996	Case report	Journal of Pediatric Hematology/Oncology	Gastric involvement in an infant with multifocal ganglioneuroblastoma
7421294	1980	Case series	Journal of Thoracic and Cardiovascular Surgery	31 patients with intrathoracic ganglioneuroblastoma treated with resection, radiation, or chemotherapy; long-term follow-up up to 25 years

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Vinca alkaloid / mitotic spindle inhibitor)
Myelosuppression Risk	Low relative to most cytotoxic agents; dose-limiting toxicity is peripheral neuropathy rather than bone marrow suppression
Emetogenicity Classification	Low
Monitoring Items	CBC, neurological exam (peripheral neuropathy, constipation/ileus), liver function; strict IV-line monitoring for extravasation (vesicant)
Handling Protection	Requires cytotoxic drug handling protocols; well-documented risk of fatality if administered intrathecally — for IV administration only, with route clearly labeled

Note: The above reflects general pharmacological knowledge of the vinca alkaloid class, as drug-specific MOA/toxicity data (DG002) is not available in this evidence pack.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data for this candidate are marked as data gaps — notably DG001, a Blocking-severity gap for TFDA label warnings/contraindications, is required before this candidate can proceed to safety initial assessment.)

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication is biologically plausible and partially corroborated by existing literature showing vincristine already used in ganglioneuroblastoma treatment protocols, but a Blocking data gap (TFDA warnings/contraindications, DG001) prevents this candidate from entering safety initial assessment (S1). No decision to proceed can be made until this gap is closed.

To proceed, the following is needed:

TFDA (or equivalent regulatory) label PDF for warnings and contraindications (DG001 — Blocking)
DrugBank-sourced detailed mechanism of action data (DG002 — High)
Confirmation of current Taiwan/US market/licensing status given “Not Marketed” flag with 0 licenses on file
Awaiting completion of ongoing Phase 3 trials (NCT03126916, NCT06172296) to upgrade evidence level beyond L3
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.